Objectives: Although vaginal estrogen is highly effective in alleviating genitourinary symptoms of menopause (GSM), some women are reluctant to use hormonal treatment. Our aim was to evaluate the effect of a zinc-containing vaginal moisturizer gel on GSM. Methods: Women with GSM were enrolled. Patients were asked to use the vaginal gel daily for 2 weeks. Vaginal Health Index (VHI) was calculated. Visual analogue scale (VAS) was obtained on vaginal pain, dryness, burning, itching, dyspareunia and dysuria before and 2 weeks after the completion of treatment. Vaginal cytology was obtained. Vulvovaginal symptom questionnaire (VSQ-21) was used to assess subjective symptoms. Results: Thirty-seven women with GSM participated in the study. The VHI improved significantly (mean ± standard deviation, 13 ± 4 before vs. 17 ± 4 after treatment, P < 0.01). The patient reported VAS combined score was significantly lower after the treatment (18 ± 14 before vs. 7 ± 12 after treatment, P < 0.01). The largest improvement occurred in vaginal dryness. The maturation value did not change significantly. There were no signs of inflammation on vaginal cytology. VSQ-21 combined scores also improved significantly (7.9 ± 5.5 before vs. 2.7 ± 3.6 after the intervention, P < 0.01). Side effects were rare and minor. 
Introduction
Vulvovaginal atrophy (VVA) is a prevalent condition affecting many postmenopausal women. 1 Up to 40% of postmenopausal women develop symptoms of VVA. [2] [3] [4] [5] It is most often diagnosed by its symptoms, including vaginal dryness, burning, itching, vagina pain and dyspareunia. More recently these symptoms have been described as a syndrome:
the genitourinary syndrome of menopause (GSM). 6, 7 This new term describes various menopausal symptoms and signs including not only genital symptoms but sexual (pain) and urinary symptoms (dysuria, urgency) as well. The pathophysiology of GSM/VVA can be explained by the decline in estrogen levels associated with diminished ovarian function and natural aging.
Traditionally the treatment options for GSM/VVA was vaginal estrogen supplementation but many women are either unable to or are afraid to use hormones. There are several nonhormonal treatment modalities for the management of VVA related symptoms, especially for one of the most Previously we investigated the role of vaginal zinc supplementation on vaginal remodeling. 9 We showed that in human vaginal smooth muscle cells, zinc has a beneficial effect on the production of extracellular components produced by the muscle at 20 μM zinc tissue level, thereby increasing the amount of elastin production. 10 Earlier animal studies have shown that zinc plays an important role in the vaginal extracellular matrix (ECM) composition. When rats were kept on a zinc-lacking diet, the vaginal structure became similar to the menopausal vagina. 11 With vaginal zinc replacement, the vaginal ECM could be regenerated with characteristics equivalent to juvenile rats. 9 The primary aim of this pilot study was to test the effect of a novel zinc-containing vaginal gel on GSM/ VVA symptoms. Secondary objectives included identifying potential side effects and safety concerns with its use. as mean values (± SD) if not otherwise specified.
Materials and Methods

Results
All patients were in menopause. The average age was 60 ± 9 years, and on average 11 ± 9 years had passed since their last menstrual period. The rest of the demographic information is as described in Table 1 . The VHI improved significantly (13 ± 4 before vs. 17 ± 4 after completion of treatment, P < 0.01; Table 2 ). The largest incremental VHI component change occurred in vaginal moisture. In sixty percent of the women, the vaginal pH remained normalized (pH < 4.6) even 2 weeks after cessation of treatment.
The patient reported VAS combined score was significantly lower after the treatment (18 ± 14 before vs. 7 ± 12 after treatment, P < 0.01; Table 3 ). The largest improvement occurred in vaginal dryness, followed by dyspareunia, burning and itching.
The VMI and VMV did not change significantly (Table 4 ).
There were no signs of inflammation on vaginal cytology.
VSQ-21 combined scores also improved significantly (7.9 ± 5.5 before vs. 2.7 ± 3.6 after the intervention, P < 0.01).
Again, scores significantly lower indicate symptom improvement. The data is presented as number (%) or mean ± standard deviation. Gravida: number of pregnancies, Para: number of deliveries, Csection: caesarean section, BSO: bilateral salpingo-oophorectomy. The data is presented as mean ± standard deviation.
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Based on the anonymous online questionnaire, 97% reported that during treatment their vagina was well moisturized and 94% felt that the treatment was very comfortable.
The moisturizing effect lasted for at least for 1 week after cessation of treatment in 75% of women. Eighty-two percent of participants felt more self-confident after using the gel and reported a significant improvement in the quality of the sexual relationship. Overall 92% of women were extremely satisfied or satisfied with the vaginal gel treatment. The consistency of the gel was satisfactory (not too thick or too liquid) to 85% of woman and every woman agreed that the smell of the gel was satisfactory. Side effects were rare and minor. Two women reported increased vaginal discharge.
One of those women discontinued the treatment and her symptoms resolved after that.
Discussion
Our prospective cohort pilot trial revealed that a novel performed to show their safety and efficacy. [15] [16] [17] [18] In one study that did examine the safety of personal moisturizers and lubricants, investigators found that many water-based gels are hyperosmolar and may lead to epithelial cell damage and toxicity. 18 The vaginal gel tested in our pilot trial has been rigorously evaluated and found to be nontoxic to epithelial There are several potential mechanisms how the tested gel may have caused the improvement of the GSM-related The data is presented as mean ± standard deviation. VAS: visual analogue scale (0-10, lower scores indicates less bother). 19 We have previously shown the beneficial effects of zinc on human cultured vaginal smooth muscles cells. Under culture conditions, we were able to significantly stimulate the vaginal smooth muscle cell elastin production within 48 hours after exposure to 20 μM of zinc sulfate. 10 In addition, in a rat model, we were able to improve upon the quality of the vaginal wall by vaginal zinc supplementation for 2 weeks in oophorectomized rats. 9 The vaginal wall (epithelium, lamina propria, and muscularis) was significantly thicker, the ratio of vaginal collagen I/III and I/V expressions was significantly up-regulated compared to placebo after the application of zinccontaining vaginal suppositories. 9 There are several limitations to our pilot study. First and most importantly we are limited by the small number of women enrolled. In addition, the short-term nature of the study precludes our ability to assess the long-term effects of the gel. The design of the study (single cohort without a comparison group) does not allow us to conclude whether a specific ingredient or if the placebo effect is responsible for the improved clinical signs and patient-reported subjective symptoms. Only a large-scale, randomized, placebo-controlled trial could definitively answer those questions. Lastly, even though the online, anonymous self-reported questionnaire gave an opportunity for our study participants to report on their experiences with the vaginal gel, this questionnaire has not been validated.
In summary, the novel zinc-containing vaginal moisturizing gel has significantly improved the GSM/VVA symptoms of postmenopausal women. With this pilot study, we have created the foundation for a larger comparative study. We plan to conduct a larger scale, randomized, placebo-controlled trial in the near future to assess the benefits of a zinc-containing vaginal gel compared with both a placebo group and an estrogen-containing vaginal gel group.
